Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.

Authors : Incorvaia L, Fanale D, Badalamenti G, Porta C, Olive D, De Luca I, Brando C, Rizzo M, Messina C, Rediti M, Russo A, Bazan V, Iovanna JL
Year : 2020
Journal : Oncoimmunology
Volume : 9
Pages : 1832348